- Trials with a EudraCT protocol (114)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (56)
114 result(s) found for: Calcium supplements.
Displaying page 1 of 6.
EudraCT Number: 2018-004815-33 | Sponsor Protocol Number: TransCon_PTH_TCP-201 | Start Date*: 2019-09-27 | |||||||||||
Sponsor Name:Ascendis Pharma Bone Diseases A/S | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administ... | |||||||||||||
Medical condition: Hypoparathyroidism (HP) in Adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004467-19 | Sponsor Protocol Number: CAMN107AHU01 | Start Date*: 2008-08-13 |
Sponsor Name:Novartis Hungary Ltd | ||
Full Title: An open-label, single center study of oral AMN 107 (nilotinib) in adult patients with imatinib - resistant or - intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast cri... | ||
Medical condition: adult patients with imatinib - resistant or - intolerant CML-CP, CML-AP or CML-BC | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-003380-26 | Sponsor Protocol Number: TCP-304 | Start Date*: 2021-01-05 | |||||||||||
Sponsor Name:Ascendis Pharma Bone Diseases A/S | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Admini... | |||||||||||||
Medical condition: Hypoparathyroidism in Adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) NO (Completed) FR (Completed) DE (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004178-24 | Sponsor Protocol Number: RP-OSV-02-D | Start Date*: 2013-12-27 |
Sponsor Name:Fresenius Medical Care Deutschland GmbH | ||
Full Title: Study to investigate the therapeutic equivalence of OsvaRen® tablets and OsvaRen® granules | ||
Medical condition: Hyperphosphataemia in end stage renal failure patients on extracorporeal renal replacement therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000678-27 | Sponsor Protocol Number: CABL001J12301 | Start Date*: 2021-08-10 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leuk... | |||||||||||||
Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) FI (Trial now transitioned) NL (Completed) DK (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000284-32 | Sponsor Protocol Number: SHP634-401 | Start Date*: 2018-02-05 | |||||||||||||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinan... | |||||||||||||||||||||||
Medical condition: Hypoparathyroidism | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) SE (Completed) DK (Completed) ES (Completed) NO (Completed) PT (Completed) BE (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001284-20 | Sponsor Protocol Number: BIOGIO | Start Date*: 2017-07-05 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study' | ||
Medical condition: Non small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004758-34 | Sponsor Protocol Number: CAMN107G2301 | Start Date*: 2009-03-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tu... | |||||||||||||
Medical condition: adult patients with histologically confirmed unresectable or metastatic GIST, either who have not received any prior anti-neoplastic therapy or, who experienced recurrence of GIST > 6 months after ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) SK (Completed) CZ (Completed) SE (Completed) HU (Completed) NL (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) DK (Prematurely Ended) GR (Prematurely Ended) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002766-20 | Sponsor Protocol Number: CAUY922A2101 | Start Date*: 2009-02-25 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in... | ||
Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001818-41 | Sponsor Protocol Number: CAMN107A2109 | Start Date*: 2006-01-04 |
Sponsor Name:Novartis Farmacéutica, S.A. | ||
Full Title: Estudio abierto, multicéntrico de acceso expandido de AMN107 oral en pacientes adultos con Imatinib (Glivec®/Gleevec®) para leucemia mieloide crónica intolerante o resistente en crisis blástica o f... | ||
Medical condition: Leucemia mieloide crónica en fase acelerada, en crisis blástica y en fase crónica Chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) GB (Completed) IE (Completed) CZ (Completed) SE (Completed) DK (Completed) BE (Completed) HU (Completed) AT (Completed) DE (Completed) PT (Prematurely Ended) GR (Completed) SK (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001064-27 | Sponsor Protocol Number: s55283 | Start Date*: 2013-06-25 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: Placebo-controlled trial with vitamin D to prevent worsening/relieve aromatase inhibitor-induced musculoskeletal symptoms in breast cancer patients | ||
Medical condition: aromatase inhibitor-induced musculoskeletal symptoms in postmenopausal breast cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-018798-39 | Sponsor Protocol Number: 19022010 | Start Date*: 2010-05-03 |
Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Abteilung für Endokrinologie | ||
Full Title: Correction of vitamin D deficiency in critically ill patients: a randomized, doulbe-blind, placebo-controlled trial | ||
Medical condition: Critically ill patients with vitamin D deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-000606-36 | Sponsor Protocol Number: 84421383 | Start Date*: 2008-04-07 | |||||||||||
Sponsor Name:Aarhus University Hospital, Dept of Endocrinology and Metabolism C | |||||||||||||
Full Title: Treatment of hypoparathyroidism with subcutaneous PTH (1-84) injections: effects on muscle function and quality of life | |||||||||||||
Medical condition: Hypoparathyroidism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004633-41 | Sponsor Protocol Number: CS 82-000-04 | Start Date*: 2007-12-04 |
Sponsor Name:TransPharma Medical | ||
Full Title: A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH (1-34) (Double-Blinded for 2 Different Dosages) in Comparison to Subcutaneous Inj... | ||
Medical condition: The population for this study is post-menopausal, osteoporosis-treatment naïve women and patients with osteopenia, 55 years of age to 85 years of age, inclusive, with a lumbar vertebral BMD T-sco... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: HU (Completed) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000192-33 | Sponsor Protocol Number: 20120360 | Start Date*: 2013-07-12 | ||||||||||||||||
Sponsor Name:KAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.) | ||||||||||||||||||
Full Title: A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of A... | ||||||||||||||||||
Medical condition: Chronic Kidney Disease Secondary Hyperparathyroidism (SHPT) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Completed) IT (Completed) CZ (Completed) LV (Completed) SE (Completed) AT (Completed) BE (Completed) ES (Completed) EE (Completed) DE (Completed) GR (Completed) LT (Completed) DK (Completed) HU (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001483-51 | Sponsor Protocol Number: CAMN107A2101 | Start Date*: 2005-07-12 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated ph... | |||||||||||||
Medical condition: CML in chronic phase, accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, systemic mastocytosis, or hypereosinophilic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) SE (Completed) IT (Completed) DK (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006692-20 | Sponsor Protocol Number: independant Trial (TOMIBA-TRIAL01) | Start Date*: 2007-09-06 |
Sponsor Name:St. Vincent Hospital, Medical Department II | ||
Full Title: The TOMIBA study Treatment of Osteoporotic Men With Intravenous Ibandronate An open-label, single-center, prospective Phase III study | ||
Medical condition: Osteoporosis in Men | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017775-19 | Sponsor Protocol Number: CAMN107EIC01 | Start Date*: 2010-05-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase | |||||||||||||
Medical condition: Newly diagnosed Philadelphia chromosome and/or BCR-ABL positive chronic myeloid leukaemia (CML) in chronic phase in adult patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) BE (Completed) HU (Completed) ES (Completed) FI (Completed) GB (Completed) PT (Completed) DE (Completed) SE (Completed) CZ (Completed) DK (Completed) SK (Completed) GR (Completed) AT (Completed) LT (Completed) IT (Completed) LV (Completed) SI (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002805-23 | Sponsor Protocol Number: 20120229(KAI-4169-006) | Start Date*: 2013-01-22 | ||||||||||||||||
Sponsor Name:KAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.) | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease ... | ||||||||||||||||||
Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) BE (Completed) CZ (Completed) GB (Completed) IT (Completed) DE (Completed) ES (Completed) AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003016-35 | Sponsor Protocol Number: CLBH589E2214 | Start Date*: 2008-10-07 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A. | |||||||||||||
Full Title: Estudio Fase II de Panobinostat oral, en pacientes adultos con Linfoma de Hodgkin clásico refractario/en recaida, después de fallo a dosis altas de quimioterapia con transfusión autóloga de células... | |||||||||||||
Medical condition: Linfoma de Hodgkin clásico refractario/en recaída | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) FR (Completed) BE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
